Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Gelderblom

Showing results (141-150 of 251) with videos related to

Pageof 26
Sort By:
Cancer Treatment Reviews|November 22, 2011
Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic reviewJ M Baas, L L Krens, H-J Guchelaar, et al.
European Journal of Radiology|September 8, 2023
Characterization of denosumab treatment response in giant cell tumors of bone with dynamic contrast-enhanced MRIG M Kalisvaart, L van der Heijden, A Navas Cañete, et al.
Cancer Epidemiology|January 26, 2024
Incidence and centralization of chordoma in the Netherlands: A nationwide study between 1991 and 2020A Lipplaa, R J P van der Wal, A D G Krol, et al.
British Journal of Cancer|May 21, 2010
Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignanciesP Hamberg, N Steeghs, W J Loos, et al.
Investigational New Drugs|September 21, 2015
Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patientsJ M Baas, L L Krens, A J ten Tije, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2003
Influence of the cisplatin hydration schedule on topotecan pharmacokineticsH Gelderblom, W J Loos, A Sparreboom, et al.
Haematology and Blood Transfusion|January 1, 1987
LAV/HTLV-III: fine-structure analysis, localization of structural proteins, and detection of envelope antigens by patient seraG Pauli, E Hausmann, R Weiss, et al.
Cancer Research|April 10, 1999
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implicationsA Sparreboom, L van Zuylen, E Brouwer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 27, 2010
First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group studyJ R Kroep, M Ouali, H Gelderblom, et al.
European Journal of Cancer (Oxford, England : 1990)|November 13, 2012
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysisM Montemurro, H Gelderblom, U Bitz, et al.
Pageof 26

Showing results (141-150 of 251) with videos related to

Sort By:
Pageof 26
Cancer Treatment Reviews|November 22, 2011
Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic reviewJ M Baas, L L Krens, H-J Guchelaar, et al.
European Journal of Radiology|September 8, 2023
Characterization of denosumab treatment response in giant cell tumors of bone with dynamic contrast-enhanced MRIG M Kalisvaart, L van der Heijden, A Navas Cañete, et al.
Cancer Epidemiology|January 26, 2024
Incidence and centralization of chordoma in the Netherlands: A nationwide study between 1991 and 2020A Lipplaa, R J P van der Wal, A D G Krol, et al.
British Journal of Cancer|May 21, 2010
Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignanciesP Hamberg, N Steeghs, W J Loos, et al.
Investigational New Drugs|September 21, 2015
Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patientsJ M Baas, L L Krens, A J ten Tije, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2003
Influence of the cisplatin hydration schedule on topotecan pharmacokineticsH Gelderblom, W J Loos, A Sparreboom, et al.
Haematology and Blood Transfusion|January 1, 1987
LAV/HTLV-III: fine-structure analysis, localization of structural proteins, and detection of envelope antigens by patient seraG Pauli, E Hausmann, R Weiss, et al.
Cancer Research|April 10, 1999
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implicationsA Sparreboom, L van Zuylen, E Brouwer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 27, 2010
First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group studyJ R Kroep, M Ouali, H Gelderblom, et al.
European Journal of Cancer (Oxford, England : 1990)|November 13, 2012
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysisM Montemurro, H Gelderblom, U Bitz, et al.
Pageof 26